Oncolix Seeks Funding for Prolactin Antagonist Trials

Five years after its founding and 15 years after work started on its lead compound, Oncolix Inc. is finally reaching out to venture capitalists for funding. The Houston-based start-up has thus far managed without big-money backers because the academics and contractors who've come into contact with its prolactin antagonist Prolanta (G129R) have been eager to lend their support.